Cambridge Antibody Technology is to set up a new 92,000 sq ft research and manufacturing centre at Granta Park in Cambridge by 2008, as part of an expansion programme that will create 300 jobs.
Cambridge Antibody Technology is to sell an 11% equity stake to Genzyme of the US for £23m, as part of a collaboration between the two companies in the development of drugs for fibrotic diseases.
Cambridge Antibody Technology has offered to acquire Oxford Glycosciences for £110m, and the group's combined cash reserve of £260m will be used to license new drugs or acquire another biotechnology company.
Cambridge Antibody Technology is looking to make a substantial acquisition in order to increase the number of products in clinical development and speed up its path to profitability.
Cambridge Antibody Technology is planning to increase research spending by 60%, raise headcount from 270 to 300 and consolidate its Cambridgeshire operations onto one site.
Cambridge Antibody Technology is to acquire Drug Royalty Corporation of Canada for £55m.
Cambridge Antibody Technology is forming an alliance with Immunex of the US to develop antibody-based treatments for auto-immune and inflammatory disorders.
Cambridge Antibody Technology is planning to use existing funds of £155m to nearly double its staff to 250 and to increase spending on drug research.
Cambridge Antibody Technology is to relocate its Cambridgeshire headquarters from Melbourn to Granta Park in Great Abington over the next two years, which will involve the relocation of 180 jobs and the creation of 70 new jobs.
Cambridge Antibody Technology is planning to raise £100m in a share offer and listing on Nasdaq, in order to fund its transformation into a fully integrated pharmaceuticals group.
Cambridge Antibody Technology is forming an alliance with Human Genome Sciences of the US to develop new pharmaceutical products using CAT's technology.
Cambridge Antibody Technology is forming a partnership with Monsanto of the US to work on the development of therapeutic drugs, and Monsanto will acquire a 6.9% stake in CAT for £7.8m.
Cambridge Antibody Technology is to form an alliance with Human Genome Sciences of the US to develop medicines from human monoclonal antibodies.
Cambridge Antibody Technology is to collaborate with Wyeth-Ayerst Laboratories in the development of a range of human antibody-based drugs.
Cambridge Antibody Technology has announced a new technology called ProAb that enables scientists to scan the body for concentrations of proteins that could be contributing to the progress of disease.
Cambridge Antibody Technology has won UK approval to start clinical trials for a treatment for proliferative vitreo retinopathy, an eye disease.
Cambridge Antibody Technology has raised £41m in a share placing and will use the funds to develop its own range of therapeutics.
Cambridge Antibody Technology is planning to raise up to £35m in a flotation in the first half of this year, but expects that further funds will be needed before it can launch one of its biotechnology products.
Cambridge Antibody Technology has agreed to license its library of human single chain antibodies to Eli Lilly in return for a fee.